الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 118 |  |  |
| | | from | 118 | | |
Abstract
Chronic hepatitis C virus (HCV) infection affects an estimated one hundred and seventy million people around the worldIn Egypt, HCV is a serious health problem where HCV prevalence is very highChronic HCV infection is associated with a high risk for liver-related mortality because of a of complicationsThe landscape of treatment has evolved substantially since the introduction of highly active direct-acting antivirals (DAAs) in 2011. The goals of treatment aim at viral eradication, delay fibrosis progression, alleviate symptoms, prevent complications, minimize all-cause mortality, and ultimately maximize the quality-of-lifeThe current longitudinal, observational cohort study included 50 patients with chronic HCV and was eligible for therapy with DAAs in form of Sofosbuvir and Daclatasvir plus weight based ribavirin. Mean age of those patients was 44.87 ± 14.55 years and majority (68%) of them was males. Sustained virological response (SVR) was obtained in all patients. our study focused on changes in hematological profile and changes in peripheral mononuclear cell phenotypes (PBMC) during DAA therapyAs regarding hematological changes in the current study, it was found that Anaemia, thrombocytopenia and leucopenia were the most reported adverse effects were noticed during course of therapy and may require dose adjustment in some patients.Also we do LFTs and we found a significant reduction in level of alanine transaminase and aspartate transaminase was noticed in the current study after therapy with insignificant changes in other parameters of liver function tests.